PolyPid reports Q3 2026 results, D-PLEX100 FDA review on track for November 28 PDUFA date
PolyPid says labeling talks with FDA are proceeding on schedule, Azurity is readying a U.S. launch, and PolyPid has regained European commercial rights to D-PLEX100.
PolyPid Ltd. reported financial results for the third quarter of 2026 alongside a corporate update dated November 11, 2026. The FDA is reviewing the New Drug Application for D-PLEX100 for prevention of surgical site infections in colorectal surgery patients under Priority Review, with a PDUFA goal date of November 28, 2026.1 The company said discussions with the FDA over labeling are ongoing and that all planned FDA interactions remain on schedule to meet that goal date.1
Pending approval, PolyPid and partner Azurity Pharmaceuticals are readying a U.S. launch of D-PLEX100 in early 2027, with Azurity assembling a commercial team that already has relationships with over 1,700 U.S. hospitals and academic medical centers.1 PolyPid has also filed for a New Technology Add-on Payment from CMS, with a decision expected in August 2027.1
On the European side, PolyPid submitted its Marketing Authorization Application to the EMA on September 14, 2026, which the agency validated after quarter end, starting formal review; a decision is expected in the second half of 2027.1 Separately, PolyPid and ADVANZ PHARMA agreed to end their 2022 licensing and supply deal covering D-PLEX100 in Europe, returning exclusive European rights to PolyPid.1
On October 28, 2026, PolyPid held an investor event outlining a 2030 growth strategy that includes a new pipeline candidate, PD01B, aimed at moderate to severe diabetic foot infections following wound debridement, expected to advance under its own NDA separate from D-PLEX100.1
On financials, PolyPid held $15.5 million in cash, equivalents and short-term deposits as of September 30, 2026, up from $12.9 million at year-end 2025, after receiving an additional $15 million milestone payment from Azurity following FDA acceptance of the NDA.1 The company said its cash position, combined with expected proceeds under the Azurity agreement and other potential future proceeds, should fund operations into 2028 and through several anticipated milestones.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.